Ischemic versus non-ischemic cardiomyopathy - Are there differences in prognosis? Experience of an advanced heart failure center;Miocardiopatia de etiologia isquémica versus não- isquémica - Haverá diferenças no prognóstico? Experiência de um centro de insuficiência cardíaca avançada [13]

Revista Portuguesa de Cardiologia

Volumn 30, Issue 2, 2011, Pages 181-197

  Lourenço, Carolina ^a   Saraiva, Fatima ^a   Martins, Hélia ^a   Baptista, Rui ^a   Costa, Susana ^a   Coelho, Lourenço ^a   Vieira, Henrique ^a   Monteiro, Pedro ^a   Franco, Fátima ^a   Gonçalves, Lino ^a   Providência, Luís A ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Ischemic cardiomyopathy; Non ischemic cardiomyopathy; Prognosis

Indexed keywords

AMINOTRANSFERASE; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; NITRATE; SODIUM;

ANEMIA; ARTICLE; CARDIOGENIC SHOCK; CARDIOMYOPATHY; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DYSLIPIDEMIA; ELECTROCARDIOGRAM; FOLLOW UP; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART TRANSPLANTATION; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MORTALITY; PREDICTION; PROGNOSIS; RETROSPECTIVE STUDY; SMOKING; SURVIVAL;

CARDIAC CARE FACILITIES; CARDIOMYOPATHIES; FEMALE; HEART FAILURE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; HYPONATREMIA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PORTUGAL; PROGNOSIS; RETROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79955451767     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008: 29;2388-2442.
2. Jessup M, Abraham WT, Casey DE, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults - A Report of the American College of Cardiology Foundation/American Heart Association. J Am Coll Cardiol. 2009; 53:e1-90.
3. Ceia F, Fonseca C, Mota T, et al., on behalf of the EPICA investigators. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail 2002; 4:531-539. (Pubitemid 36564974)
4. Murdoch DR, Love MP, Robb SD, et al. Importance of heart failure as a cause of death. Changing contribution to overall mortality and coronary heart disease mortality in Scotland 1979-1992. Eur Heart J 1998;19:1829-1835.
5. Chwan AC, Sindone AP, Wong HS, Freedman SB. Differences in management and outcome of ischemic and non-ischemic cardiomyopathy. Int J Cardiol. 2008;26;129(2):198-204.
6. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-402. (Pubitemid 35239711)
7. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285: 1441-1446.
8. Stewart S, MacIntyre K, Hole DJ, et al. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001;3:315-322.
9. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13. (Pubitemid 36835815)
10. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
11. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994;90:1765-73.
12. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-56.
13. Nony P, Boissel JP, Girard et al. P, Relative efficacy of angiotensin converting enzyme inhibitors on mortality of patients with congestive heart failure: implications of randomized trials and role of the aetiology (ischaemic or non-ischaemic) of heart failure. Eur Heart J 1992;13:1101-8.
14. Follath F, Cleland JG, Klein W, Murphy R. Etiology and response to drug treatment in heart failure. J Am Coll Cardiol. 1998;32(5):1167-72. (Pubitemid 28522369)
15. Abraham WT, Singh B. Ischemic and nonischemic heart failure do not require different treatment strategies. J Cardiovasc Pharmacol. 1999;33 Suppl 3:S1-7.
16. Bart B, Shaw AB, Mccants CB, et al. Clinical Determinants of Mortality in Patients With Angiographically Diagnosed Ischemic or Nonischemic Cardiomyopathy. J Am Coll Cardiol 1997;30 (4):1002-8. (Pubitemid 27435894)
17. Stevenson LW, Tillisch JH, Hamilton M, et al. Importance of hemodynamic response to therapy in predicting survival with ejection fraction <20% secondary to ischemic or nonischemic dilated cardiomyopathy. Am J Cardiol 1990; 66:1348-1354.
18. Likoff MJ, Chandler SL and Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 1987; 59:634-638. (Pubitemid 17047334)
19. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993;22:6A-13A.
20. Miller WL, Hartman KA, Burritt MF, et al. Troponin, B-type natriuretic peptides and outcomes in severe heart failure: differences between ischemic and dilated cardiomyopathies. Clin Cardiol. 2007;30(5):245-50.
21. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: Prediction of Survival in Heart Failure. Circulation 2006; 113:1424-1433. (Pubitemid 43739439)
22. Deng MC, Brisse B, Erren M, et al. Ischemic versus idiopathic cardiomyopathy: differing neurohumoral profiles despite comparable peak oxygen uptake. Int J Cardiol. 1997;10;61(3):261-8. (Pubitemid 27433462)
23. Yancy CW, Fonarow GC. Quality of Care and Outcomes in Acute Decompensated Heart Failure: The ADHERE Registry. Current Heart Failure Reports 2004, 1:121-128.
24. Abraham WT, Fonarow GC, Albert NM, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;29; 52(5):347-56. (Pubitemid 352005813)
25. Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the Guidelines program. Circ Cardiovasc Qual Outcomes. 2010; 3(1):25-32.
26. Velavan P, Khan NK, Goode K, et al. Predictors of short term mortality in heart failure - insights from the Euro Heart Failure survey. Int J Cardiol. 2010; 7;138(1):63-9.
27. O'Connor CM, Abraham WT, Albert NM, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2008; 156(4):662-73.
28. Gustafsson F, Schou M, Videbaek L, et al. Incidence and predictors of hospitalization or death in patients managed in multidisciplinary heart failure clinics. Eur J Heart Fail. 2009;11(4):413-9.
29. Siirila-Waris K, Lassus J, Melin J, et al. for the FINN-AKVA Study Group. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J. 2006; 27(24):3011-7.
30. Mullens W, Abrahams Z, Skouri HN, et al. Prognostic evaluation of ambulatory patients with advanced heart failure. Am J Cardiol. 2008;1;101(9):1297-302.